Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 12

1.

Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.

Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E; Cross Trial Safety Assessment Group.

Circulation. 2008 Apr 22;117(16):2104-13. doi: 10.1161/CIRCULATIONAHA.108.764530. Epub 2008 Mar 31.

PMID:
18378608
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.

Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R.

J R Soc Med. 2006 Mar;99(3):132-40. Review.

PMID:
16508052
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.

Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS.

Health Technol Assess. 2008 Apr;12(11):1-278, iii. Review.

PMID:
18405470
[PubMed - indexed for MEDLINE]
Free Article
4.

Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.

McCormack PL.

Drugs. 2011 Dec 24;71(18):2457-89. doi: 10.2165/11208240-000000000-00000. Review.

PMID:
22141388
[PubMed - indexed for MEDLINE]
5.

Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.

Matchaba P, Gitton X, Krammer G, Ehrsam E, Sloan VS, Olson M, Mellein B, Hoexter G, Orloff J, Garaud JJ.

Clin Ther. 2005 Aug;27(8):1196-214. Review.

PMID:
16199245
[PubMed - indexed for MEDLINE]
6.

[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].

Valat JP, Deray G, Héloire F.

Presse Med. 2006 Sep;35(9 Spec No 1):1S25-34. Review. French.

PMID:
17078592
[PubMed - indexed for MEDLINE]
7.

Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor.

Whelton A, Maurath CJ, Verburg KM, Geis GS.

Am J Ther. 2000 May;7(3):159-75. Review. Erratum in: Am J Ther 2000 Sep;7(5):341.

PMID:
11317165
[PubMed - indexed for MEDLINE]
8.

What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.

Hochberg MC.

Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S15-22. Review.

PMID:
11695246
[PubMed - indexed for MEDLINE]
9.

Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.

Mallen SR, Essex MN, Zhang R.

Curr Med Res Opin. 2011 Jul;27(7):1359-66. doi: 10.1185/03007995.2011.581274. Epub 2011 May 12. Review.

PMID:
21561397
[PubMed - indexed for MEDLINE]
10.

Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor.

Mukherjee D.

Thromb Haemost. 2006 Oct;96(4):407-12. Review.

PMID:
17003915
[PubMed - indexed for MEDLINE]
11.

Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.

Bannwarth B, Berenbaum F.

Expert Opin Investig Drugs. 2005 Apr;14(4):521-33. Review.

PMID:
15882125
[PubMed - indexed for MEDLINE]
12.

COX-2 selective inhibitors and heart health.

Simon LS, White WB.

Postgrad Med. 2005 Jan;117(1 Suppl):7-20. doi: 10.3810/pgm.01.2005.suppl40.201. Review.

PMID:
19667717
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk